We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Automated Hematology Analyzer Quantifies Immature Granulocytes

By LabMedica International staff writers
Posted on 05 May 2010
Print article
An automated hematology analyzer's immature granulocyte (IG) parameter provides the effective detection and quantification of circulating immature granulocytes that may be used by physicians as an early indicator of acute infection, inflammatory response, or myeloproliferative disorder.

Sysmex America, Inc. (Mundelein, IL, USA), a medical diagnostic instrument manufacturer and information systems developer, announced that its Sysmex XT-4000i automated hematology analyzer has been cleared by the U.S. Food and Drug Administration (FDA). The Sysmex XT-4000i provides 34 parameters, including the advanced clinical parameters, IG and RET-He (reticulocyte hemoglobin equivalent), and a body fluid specific mode. It utilizes Sysmex's patented fluorescent flow cytometry and advanced cell counting methods to deliver rapid, reliable results essential in patient diagnosis and therapeutic monitoring.

"With FDA's clearance of the Sysmex XT-4000i, we are truly in a unique position to offer a portfolio of hematology products that support the needs of small clinics to high-volume clinical laboratories in every sized hospital or integrated delivery network in the nation. Additionally, the Sysmex XT-4000i offers the reliability and standardization of Sysmex's patented flow cytometry technology platform, thereby enhancing efficiency and improving productivity without sacrificing quality or accuracy,” said John Kershaw, president and CEO, Sysmex America.

The system's RET-He parameter, which quantifies the hemoglobin content of reticulocytes, is an established parameter in the U.S. National Kidney Foundation's KDOQI (Kidney Disease Outcomes Quality Initiative) guidelines for assessing the initial iron status of patients with chronic kidney disease on hemodialysis as well as intravenous iron replacement in these patients.

Sysmex America, the U.S. headquarters of Sysmex Corp. (Kobe, Japan), is a world leader in clinical laboratory systemization and solutions, including clinical diagnostics, automation, and information systems. Sysmex focuses on extending the boundaries of diagnostic science while providing the management information tools that make a real difference in clinical and operational results for people worldwide.

Related Links:

Sysmex America


New
Gold Member
Human Chorionic Gonadotropin Test
hCG Quantitative - R012
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Immunofluorescence Analyzer
MPQuanti
New
Community-Acquired Pneumonia Test
RIDA UNITY CAP Bac

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.